Ligand Enters into Worldwide OmniAb Platform License Agreement with Glenmark Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with its worldwide OmniAb Platform License Agreement with Glenmark Pharmaceuticals for human antibody discovery using transgenic rodents and chickens. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Glenmark is a global innovative pharmaceutical company with operations in more than 50 countries.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.